celecoxib has been researched along with Carcinoma in 26 studies
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the synergistic cytotoxicity of cis-dichlorodiamine platinum (DDP) and celecoxib on nasopharyngeal carcinoma TW03 cell which is resistant to DDP (TW03/DDP)." | 7.81 | [Combined application of cisplatin and celecoxib inhibits the proliferation and promotes apoptosis of nasopharyngeal carcinoma cells resistant to cisplatin]. ( Chen, J; Li, Q; Liu, S; Peng, J, 2015) |
| "The cell colony formation assay after the combination of celecoxib and radiation treatment was done on C666-1, CNE-1 and CNE-2 nasopharyngeal carcinoma cells, which expressed different COX-2 levels." | 7.80 | Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma. ( Chen, WB; Huang, B; Liang, CH; Qiu, QH; Zhang, SX, 2014) |
| "To investigate the mechanisms underlying the anticancer effect of celecoxib on nasopharyngeal carcinoma (NPC)." | 7.78 | Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. ( Hu, GQ; Hu, GY; Liu, DB; Long, GX; Mei, Q; Qiu, H, 2012) |
| "The aim of the study is to determine the effect of Celecoxib administration, dietary or topical, on expression of Ki-67, c-erb-B2, bcl-2 and bax genes in rat tongue by the immunohistochemistry methods and also tdt-mediated dupt-biotin nick end labeling assay in order to explore their role in malignant transformation and the proliferation rate, apoptosis rate in tongue squamous cell carcinoma." | 7.75 | Effect of dietary and topical Celecoxib on expression of bcl-2, bax, c-erb-B2 and Ki67 in carcinogen-induced tongue carcinoma in rat. ( Abbasi, MM; Aydemir, I; Dustar, Y; Javadzadeh, BY; Kalati, FA; Khaki, AA; Rad, JS; Roshangar, L; Sohrabi, M; Tuglu, IM; Vatansever, S, 2009) |
| "This study was performed to evaluate whether down-regulation of prostaglandin E(2) (PGE(2)) synthesis by celecoxib treatment is associated with inhibition of cell growth in human colon carcinoma cell lines." | 7.74 | Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. ( Arber, N; Ben-Yosef, R; Kazanov, D; Lev-Ari, S; Liberman, E, 2007) |
| "To evaluate the role of celecoxib on 15-lipoxygenase-1 (15-LOX-1) expression, protein levels, and rates of apoptosis in colorectal cancer cell lines." | 7.73 | Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. ( Arnoletti, JP; Bland, KI; Boedefeld, W; Frolov, A; Hawkins, A; Heslin, MJ; Soong, R; Urist, MM, 2005) |
| "Local recurrence in colon cancer causes poor prognosis affecting overall survival of cancer-affected patient population." | 5.43 | Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. ( Chaurasia, M; Chowdhury, T; Das, S; Dey, KK; Mandal, M; Pal, I; Parida, S; Rajesh, Y; Sharma, K, 2016) |
| "Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied." | 5.40 | Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 5.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| "To investigate the synergistic cytotoxicity of cis-dichlorodiamine platinum (DDP) and celecoxib on nasopharyngeal carcinoma TW03 cell which is resistant to DDP (TW03/DDP)." | 3.81 | [Combined application of cisplatin and celecoxib inhibits the proliferation and promotes apoptosis of nasopharyngeal carcinoma cells resistant to cisplatin]. ( Chen, J; Li, Q; Liu, S; Peng, J, 2015) |
| "The cell colony formation assay after the combination of celecoxib and radiation treatment was done on C666-1, CNE-1 and CNE-2 nasopharyngeal carcinoma cells, which expressed different COX-2 levels." | 3.80 | Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma. ( Chen, WB; Huang, B; Liang, CH; Qiu, QH; Zhang, SX, 2014) |
| "To investigate the mechanisms underlying the anticancer effect of celecoxib on nasopharyngeal carcinoma (NPC)." | 3.78 | Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. ( Hu, GQ; Hu, GY; Liu, DB; Long, GX; Mei, Q; Qiu, H, 2012) |
| "Celecoxib combined with radiotherapy could induce apoptosis and enhance the radiosensitivity of human nasopharyngeal carcinoma CNE-2Z cell lines." | 3.77 | [Effects of celecoxib combined with radiotherapy on apoptosis of CNE-2Z cell lines]. ( Gui, P; Peng, P; Wei, LZ; Xiang, YZ; Xiong, ZJ; Yu, L, 2011) |
| "The aim of the study is to determine the effect of Celecoxib administration, dietary or topical, on expression of Ki-67, c-erb-B2, bcl-2 and bax genes in rat tongue by the immunohistochemistry methods and also tdt-mediated dupt-biotin nick end labeling assay in order to explore their role in malignant transformation and the proliferation rate, apoptosis rate in tongue squamous cell carcinoma." | 3.75 | Effect of dietary and topical Celecoxib on expression of bcl-2, bax, c-erb-B2 and Ki67 in carcinogen-induced tongue carcinoma in rat. ( Abbasi, MM; Aydemir, I; Dustar, Y; Javadzadeh, BY; Kalati, FA; Khaki, AA; Rad, JS; Roshangar, L; Sohrabi, M; Tuglu, IM; Vatansever, S, 2009) |
| "This study was performed to evaluate whether down-regulation of prostaglandin E(2) (PGE(2)) synthesis by celecoxib treatment is associated with inhibition of cell growth in human colon carcinoma cell lines." | 3.74 | Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. ( Arber, N; Ben-Yosef, R; Kazanov, D; Lev-Ari, S; Liberman, E, 2007) |
| "To evaluate the role of celecoxib on 15-lipoxygenase-1 (15-LOX-1) expression, protein levels, and rates of apoptosis in colorectal cancer cell lines." | 3.73 | Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. ( Arnoletti, JP; Bland, KI; Boedefeld, W; Frolov, A; Hawkins, A; Heslin, MJ; Soong, R; Urist, MM, 2005) |
| "Local recurrence in colon cancer causes poor prognosis affecting overall survival of cancer-affected patient population." | 1.43 | Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma. ( Chaurasia, M; Chowdhury, T; Das, S; Dey, KK; Mandal, M; Pal, I; Parida, S; Rajesh, Y; Sharma, K, 2016) |
| "Celecoxib is a selective inhibitor of COX-2, whose connection with the development and progression of human tumors has been extensively studied." | 1.40 | Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. ( Gan, L; Hu, GQ; Hu, GY; Jiang, JZ; Li, WW; Liu, DB; Long, GX; Mei, Q; Sun, W; Wang, JF, 2014) |
| "The underlying causes of endometrial cancer (EMC) are poorly understood, and treatment options for patients with advanced stages of the disease are limited." | 1.40 | Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer. ( Cappelletti, M; Daikoku, T; Dey, SK; Ellenson, LH; Hossain, MM; Terakawa, J; Yang, P; Yoshie, M, 2014) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 1.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Imaduddin, M | 1 |
| Sultania, M | 1 |
| Vigneshwaran, B | 1 |
| Muduly, DK | 1 |
| Kar, M | 1 |
| Hauser, P | 1 |
| Vancsó, I | 1 |
| Pócza, T | 1 |
| Schuler, D | 1 |
| Garami, M | 1 |
| Li, WW | 1 |
| Long, GX | 2 |
| Liu, DB | 2 |
| Mei, Q | 2 |
| Wang, JF | 1 |
| Hu, GY | 2 |
| Jiang, JZ | 1 |
| Sun, W | 1 |
| Gan, L | 1 |
| Hu, GQ | 2 |
| Zhang, SX | 1 |
| Qiu, QH | 1 |
| Chen, WB | 1 |
| Liang, CH | 1 |
| Huang, B | 1 |
| Daikoku, T | 1 |
| Terakawa, J | 1 |
| Hossain, MM | 1 |
| Yoshie, M | 1 |
| Cappelletti, M | 1 |
| Yang, P | 2 |
| Ellenson, LH | 1 |
| Dey, SK | 1 |
| Chen, J | 1 |
| Liu, S | 1 |
| Li, Q | 1 |
| Peng, J | 1 |
| Pal, I | 1 |
| Dey, KK | 1 |
| Chaurasia, M | 1 |
| Parida, S | 1 |
| Das, S | 1 |
| Rajesh, Y | 1 |
| Sharma, K | 1 |
| Chowdhury, T | 1 |
| Mandal, M | 1 |
| Brown, PH | 1 |
| Subbaramaiah, K | 1 |
| Salmon, AP | 1 |
| Baker, R | 1 |
| Newman, RA | 1 |
| Zhou, XK | 1 |
| Bissonnette, RP | 1 |
| Dannenberg, AJ | 1 |
| Howe, LR | 1 |
| Grushka, JR | 1 |
| Ryckman, J | 1 |
| Mueller, C | 1 |
| Roessingh, Ade B | 1 |
| Walton, JM | 1 |
| St Vil, D | 1 |
| Laberge, JM | 1 |
| Bernard, C | 1 |
| Nguyen, VH | 1 |
| Puligandla, PS | 1 |
| Sohrabi, M | 1 |
| Kalati, FA | 1 |
| Vatansever, S | 1 |
| Abbasi, MM | 1 |
| Roshangar, L | 1 |
| Khaki, AA | 1 |
| Tuglu, IM | 1 |
| Aydemir, I | 1 |
| Dustar, Y | 1 |
| Javadzadeh, BY | 1 |
| Rad, JS | 1 |
| Bidard, FC | 1 |
| Mathiot, C | 1 |
| Delaloge, S | 1 |
| Brain, E | 1 |
| Giachetti, S | 1 |
| de Cremoux, P | 1 |
| Marty, M | 1 |
| Pierga, JY | 1 |
| Bocca, C | 1 |
| Bozzo, F | 1 |
| Bassignana, A | 1 |
| Miglietta, A | 1 |
| Xiang, YZ | 1 |
| Wei, LZ | 1 |
| Yu, L | 1 |
| Gui, P | 1 |
| Peng, P | 1 |
| Xiong, ZJ | 1 |
| Qiu, H | 1 |
| Lönnroth, C | 1 |
| Andersson, M | 1 |
| Nordgren, S | 1 |
| Lundholm, K | 1 |
| Lasalvia-Prisco, E | 1 |
| Goldschmidt, P | 1 |
| Galmarini, F | 1 |
| Cucchi, S | 1 |
| Vázquez, J | 1 |
| Aghazarian, M | 1 |
| Lasalvia-Galante, E | 1 |
| Golomar, W | 1 |
| Gordon, W | 1 |
| Hashitani, S | 1 |
| Urade, M | 1 |
| Nishimura, N | 1 |
| Maeda, T | 1 |
| Takaoka, K | 1 |
| Noguchi, K | 1 |
| Sakurai, K | 1 |
| Davis, TW | 1 |
| O'Neal, JM | 1 |
| Pagel, MD | 1 |
| Zweifel, BS | 1 |
| Mehta, PP | 1 |
| Heuvelman, DM | 1 |
| Masferrer, JL | 1 |
| Roh, JL | 1 |
| Sung, MW | 1 |
| Kim, KH | 1 |
| Heslin, MJ | 1 |
| Hawkins, A | 1 |
| Boedefeld, W | 1 |
| Arnoletti, JP | 1 |
| Frolov, A | 1 |
| Soong, R | 1 |
| Urist, MM | 1 |
| Bland, KI | 1 |
| Maiello, E | 1 |
| Gebbia, V | 1 |
| Giuliani, F | 1 |
| Paoletti, G | 1 |
| Gebbia, N | 1 |
| Borsellino, N | 1 |
| Cartenì, G | 1 |
| Pezzella, G | 1 |
| Manzione, L | 1 |
| Romito, S | 1 |
| Lopez, M | 1 |
| Colucci, G | 1 |
| Tsutsumi, S | 1 |
| Namba, T | 1 |
| Tanaka, KI | 1 |
| Arai, Y | 1 |
| Ishihara, T | 1 |
| Aburaya, M | 1 |
| Mima, S | 1 |
| Hoshino, T | 1 |
| Mizushima, T | 1 |
| Casanova, I | 1 |
| Parreño, M | 1 |
| Farré, L | 1 |
| Guerrero, S | 1 |
| Céspedes, MV | 1 |
| Pavon, MA | 1 |
| Sancho, FJ | 1 |
| Marcuello, E | 1 |
| Trias, M | 1 |
| Mangues, R | 1 |
| Raskov, HH | 1 |
| Lev-Ari, S | 1 |
| Kazanov, D | 1 |
| Liberman, E | 1 |
| Ben-Yosef, R | 1 |
| Arber, N | 1 |
| Riedel, SB | 1 |
| Fischer, SM | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
2 reviews available for celecoxib and Carcinoma
| Article | Year |
|---|---|
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Ch | 2009 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2006 |
3 trials available for celecoxib and Carcinoma
| Article | Year |
|---|---|
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Carci | 2012 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Col | 2005 |
21 other studies available for celecoxib and Carcinoma
| Article | Year |
|---|---|
Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
Topics: Carcinoma; Celecoxib; Cisplatin; COVID-19; Humans; Methotrexate; Mouth Neoplasms; Neoplasm Recurrenc | 2021 |
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera | 2013 |
Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity.
Topics: Carcinoma; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coloring Agents; Cyclooxy | 2014 |
Celecoxib enhances radiosensitivity via induction of G₂-M phase arrest and apoptosis in nasopharyngeal carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Celecoxib; Cell Cycle Checkpoints; Cell Division; Cell | 2014 |
Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma; Celecoxib; Cell Line, | 2014 |
[Combined application of cisplatin and celecoxib inhibits the proliferation and promotes apoptosis of nasopharyngeal carcinoma cells resistant to cisplatin].
Topics: Antineoplastic Agents; Carcinoma; Celecoxib; Cell Proliferation; Cisplatin; Drug Resistance, Neoplas | 2015 |
Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma.
Topics: Apoptosis; Benzimidazoles; Carcinoma; Celecoxib; Colonic Neoplasms; Combined Modality Therapy; DNA B | 2016 |
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma; Celecoxib; Cell Tran | 2008 |
Effect of dietary and topical Celecoxib on expression of bcl-2, bax, c-erb-B2 and Ki67 in carcinogen-induced tongue carcinoma in rat.
Topics: Animal Feed; Animals; Anti-Inflammatory Agents, Non-Steroidal; bcl-2-Associated X Protein; Carcinoge | 2009 |
Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cell | 2011 |
[Effects of celecoxib combined with radiotherapy on apoptosis of CNE-2Z cell lines].
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Celecoxib; Cell Line, Tumor; Humans; Na | 2011 |
Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Celecoxib; Cell Cycle Checkpoints; C | 2012 |
Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Bioma | 2012 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Topics: Animals; Antineoplastic Agents; Carcinoma; Celecoxib; Colonic Neoplasms; Combined Modality Therapy; | 2004 |
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Carcinoma, Squamous Cell; Celecoxib; Ce | 2005 |
Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer.
Topics: Adenoma; Apoptosis; Arachidonate 15-Lipoxygenase; Blotting, Western; Carcinoma; Celecoxib; Colorecta | 2005 |
Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells.
Topics: Activating Transcription Factor 4; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Calc | 2006 |
Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.
Topics: Anoikis; Carcinoma; Celecoxib; Cell Nucleus; Colonic Neoplasms; Crk-Associated Substrate Protein; Cy | 2006 |
Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Carcinoma; Celecoxib; Cel | 2007 |
Vitamin E analog, alpha-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice.
Topics: Acetates; Administration, Inhalation; Animals; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |